vs
BALCHEM CORP（BCPC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
BALCHEM CORP的季度营收约是Orthofix Medical Inc.的1.2倍（$270.7M vs $219.9M），BALCHEM CORP净利率更高（14.9% vs -1.0%，领先15.9%），BALCHEM CORP同比增速更快（8.1% vs 2.0%），BALCHEM CORP自由现金流更多（$33.8M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.5%）
Balchem Corp是一家全球特种化学品与营养原料供应商，核心业务覆盖人类营养、动物保健、制药、工业应用四大领域，为北美、欧洲、亚太等地区的客户提供定制化专用原料产品。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
BCPC vs OFIX — 直观对比
营收规模更大
BCPC
是对方的1.2倍
$219.9M
营收增速更快
BCPC
高出6.1%
2.0%
净利率更高
BCPC
高出15.9%
-1.0%
自由现金流更多
BCPC
多$17.0M
$16.8M
两年增速更快
OFIX
近两年复合增速
7.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.7M | $219.9M |
| 净利润 | $40.3M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 20.5% | 0.2% |
| 净利率 | 14.9% | -1.0% |
| 营收同比 | 8.1% | 2.0% |
| 净利润同比 | 8.7% | 92.4% |
| 每股收益（稀释后） | $1.25 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCPCOFIX
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $219.9M | ||
| Q3 25 | $267.6M | $205.6M | ||
| Q2 25 | $255.5M | $203.1M | ||
| Q1 25 | $250.5M | $193.6M | ||
| Q4 24 | $240.0M | $215.7M | ||
| Q3 24 | $239.9M | $196.6M | ||
| Q2 24 | $234.1M | $198.6M |
净利润BCPCOFIX
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $-2.2M | ||
| Q3 25 | $40.3M | $-22.8M | ||
| Q2 25 | $38.3M | $-14.1M | ||
| Q1 25 | $37.1M | $-53.1M | ||
| Q4 24 | $33.6M | $-29.1M | ||
| Q3 24 | $33.8M | $-27.4M | ||
| Q2 24 | $32.1M | $-33.4M |
毛利率BCPCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 71.1% | ||
| Q3 25 | 35.7% | 72.2% | ||
| Q2 25 | 36.4% | 68.7% | ||
| Q1 25 | 35.2% | 62.8% | ||
| Q4 24 | 36.0% | 69.0% | ||
| Q3 24 | 35.6% | 68.7% | ||
| Q2 24 | 35.5% | 67.8% |
营业利润率BCPCOFIX
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 0.2% | ||
| Q3 25 | 20.4% | -8.3% | ||
| Q2 25 | 20.1% | -7.9% | ||
| Q1 25 | 20.4% | -25.2% | ||
| Q4 24 | 19.8% | -5.3% | ||
| Q3 24 | 20.0% | -9.6% | ||
| Q2 24 | 19.6% | -12.5% |
净利率BCPCOFIX
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | -1.0% | ||
| Q3 25 | 15.1% | -11.1% | ||
| Q2 25 | 15.0% | -6.9% | ||
| Q1 25 | 14.8% | -27.4% | ||
| Q4 24 | 14.0% | -13.5% | ||
| Q3 24 | 14.1% | -13.9% | ||
| Q2 24 | 13.7% | -16.8% |
每股收益（稀释后）BCPCOFIX
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $-0.05 | ||
| Q3 25 | $1.24 | $-0.57 | ||
| Q2 25 | $1.17 | $-0.36 | ||
| Q1 25 | $1.13 | $-1.35 | ||
| Q4 24 | $1.03 | $-0.76 | ||
| Q3 24 | $1.03 | $-0.71 | ||
| Q2 24 | $0.98 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $72.9M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $450.0M |
| 总资产 | $1.7B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCPCOFIX
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $82.0M | ||
| Q3 25 | $65.1M | $62.9M | ||
| Q2 25 | $65.4M | $65.6M | ||
| Q1 25 | $49.9M | $58.0M | ||
| Q4 24 | $49.5M | $83.2M | ||
| Q3 24 | $73.7M | $30.1M | ||
| Q2 24 | $63.7M | $26.4M |
总债务BCPCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益BCPCOFIX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $450.0M | ||
| Q3 25 | $1.3B | $442.5M | ||
| Q2 25 | $1.3B | $458.3M | ||
| Q1 25 | $1.2B | $458.3M | ||
| Q4 24 | $1.1B | $503.1M | ||
| Q3 24 | $1.2B | $525.9M | ||
| Q2 24 | $1.1B | $546.0M |
总资产BCPCOFIX
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $850.6M | ||
| Q3 25 | $1.7B | $832.6M | ||
| Q2 25 | $1.7B | $837.2M | ||
| Q1 25 | $1.6B | $823.1M | ||
| Q4 24 | $1.6B | $893.3M | ||
| Q3 24 | $1.6B | $867.9M | ||
| Q2 24 | $1.6B | $882.0M |
负债/权益比BCPCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $40.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $33.8M | $16.8M |
| 自由现金流率自由现金流/营收 | 12.5% | 7.6% |
| 资本支出强度资本支出/营收 | 2.3% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流BCPCOFIX
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $27.7M | ||
| Q3 25 | $65.6M | $12.4M | ||
| Q2 25 | $47.3M | $11.6M | ||
| Q1 25 | $36.5M | $-18.4M | ||
| Q4 24 | $52.3M | $23.7M | ||
| Q3 24 | $51.3M | $11.7M | ||
| Q2 24 | $45.0M | $9.0M |
自由现金流BCPCOFIX
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率BCPCOFIX
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度BCPCOFIX
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率BCPCOFIX
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCPC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
